Twist Bioscience Corporation, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced that it raised an additional $27 million in venture financing. This close, combined with the $33 million announced in March 2017, completes the $60 million financing.
Twist Bioscience expects to use the funding to facilitate increased growth in the company’s core business of gene synthesis and increased investment into two vertical market segments of drug discovery and DNA digital data storage. To date, Twist Bioscience has raised a total of $191 million.
Demonstrating strong support from institutional, cross over and strategic investors, the funding includes a key investment from Biomatics Capital as well as new investors Reinet Fund S.C.A., F.I.S., NFT Investment Limited, KANGMEI Group, Bay City Capital, GF Xinde Life Science Investment Fund, 3W Partners Capital and Ditch Plains Capital Management LP.